STUDY OF THE SILVER BIRCHPOLLEN ALLERGOID

Olga S. Kulaga, G. E. Avoyan, D. R. Esaulova, I. V. Andreev, K.O. Nechay, A. I. Andreev, Karina B. Kicheeva, O. S. Baklakova, O. V. Mislavsky, Vladimir I. Gegechkori, N. Cherchenko, M. N. Sankov, Аndrey Yu. Toptygin, S. M. Shvets, Tatiana S. Romanova, E. Latysheva, А. Martynov, M. Khaitov
{"title":"STUDY OF THE SILVER BIRCHPOLLEN ALLERGOID","authors":"Olga S. Kulaga, G. E. Avoyan, D. R. Esaulova, I. V. Andreev, K.O. Nechay, A. I. Andreev, Karina B. Kicheeva, O. S. Baklakova, O. V. Mislavsky, Vladimir I. Gegechkori, N. Cherchenko, M. N. Sankov, Аndrey Yu. Toptygin, S. M. Shvets, Tatiana S. Romanova, E. Latysheva, А. Martynov, M. Khaitov","doi":"10.36691/rja1549","DOIUrl":null,"url":null,"abstract":"Background. Birch pollen is one of the main allergens in central Russia, Europe, North America, and in several other regions. Allergens contained in birch pollen often cause IgE cross-reactivity with homologous proteins both in other trees and in various foods. \nAllergen immunotherapy (AIT) is currently the only allergy treating method that directly affects various links in the pathogenesis of the disease, changing the body's response to the action of the allergen. The clinical effectiveness of ASIT reaches 8090% and is expressed by results in a decrease in clinical manifestations and the need for drugs. An allergoid, unlike an allergen, retains its immunogenicity, but significantly loses its allergenicity, which is makes it safer for use in with AIT. \nAim. Obtaining an allergoid from the pollen of silver birch (lat. Btula pndula), by processing it with glutaraldehyde. \nMaterials and Methods. The purified allergen isolated from pollen by degreasing and water-salt extraction was dissolved in PBS pH 7.5 and polymerized in 0.1% glutaraldehyde solution. Stabilization was carried out with a solution of sodium borohydride. \nResults. After assessing the specific activity using a competitive enzyme-linked immunosorbent assay (ELISA), it was seen that the allergoid significantly reduced its allergenicity compared to the original allergen. \nConclusions. In the course of the work, an allergen of the silver birch was obtained. The resulting allergen contains major and minor antigens of silver birch (Bet v 1, Bet v 2, Bet v 3, Bet v 6, Bet v 7). On its basis, an allergoid was obtained by polymerization with glutaraldehyde. The resulting allergoid has a large molecular weight, and also has a low allergenic activity, in comparison with the original allergen. Thereby, this allergoid can become the basis for obtaining new AIT preparations.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36691/rja1549","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background. Birch pollen is one of the main allergens in central Russia, Europe, North America, and in several other regions. Allergens contained in birch pollen often cause IgE cross-reactivity with homologous proteins both in other trees and in various foods. Allergen immunotherapy (AIT) is currently the only allergy treating method that directly affects various links in the pathogenesis of the disease, changing the body's response to the action of the allergen. The clinical effectiveness of ASIT reaches 8090% and is expressed by results in a decrease in clinical manifestations and the need for drugs. An allergoid, unlike an allergen, retains its immunogenicity, but significantly loses its allergenicity, which is makes it safer for use in with AIT. Aim. Obtaining an allergoid from the pollen of silver birch (lat. Btula pndula), by processing it with glutaraldehyde. Materials and Methods. The purified allergen isolated from pollen by degreasing and water-salt extraction was dissolved in PBS pH 7.5 and polymerized in 0.1% glutaraldehyde solution. Stabilization was carried out with a solution of sodium borohydride. Results. After assessing the specific activity using a competitive enzyme-linked immunosorbent assay (ELISA), it was seen that the allergoid significantly reduced its allergenicity compared to the original allergen. Conclusions. In the course of the work, an allergen of the silver birch was obtained. The resulting allergen contains major and minor antigens of silver birch (Bet v 1, Bet v 2, Bet v 3, Bet v 6, Bet v 7). On its basis, an allergoid was obtained by polymerization with glutaraldehyde. The resulting allergoid has a large molecular weight, and also has a low allergenic activity, in comparison with the original allergen. Thereby, this allergoid can become the basis for obtaining new AIT preparations.
白桦花粉类过敏原的研究
背景。桦树花粉是俄罗斯中部、欧洲、北美和其他几个地区的主要过敏原之一。桦树花粉中含有的过敏原通常会引起IgE与其他树木和各种食物中的同源蛋白的交叉反应。过敏原免疫疗法(AIT)是目前唯一一种直接影响疾病发病各环节,改变机体对过敏原作用的反应的过敏治疗方法。ASIT的临床疗效达到8090%,表现为临床表现减少,用药需求减少。与过敏原不同,类过敏原保留了其免疫原性,但明显失去了其致敏性,这使得它更安全地用于AIT。的目标。从白桦树的花粉中获得一种过敏原。用戊二醛处理。材料与方法。通过脱脂和水盐萃取从花粉中分离得到纯化的过敏原,将其溶解在pH 7.5的PBS中,并在0.1%戊二醛溶液中聚合。用硼氢化钠溶液进行稳定化。结果。在使用竞争性酶联免疫吸附试验(ELISA)评估特异性活性后,发现与原始过敏原相比,类过敏原的致敏性显著降低。结论。在研究过程中,获得了一种桦树过敏原。所得过敏原含有白桦主要抗原和次要抗原(betv1, betv2, betv3, betv1 6, betv1 7),在此基础上与戊二醛聚合得到类过敏原。与原过敏原相比,所得的类过敏原分子量大,且致敏活性低。因此,该类过敏原可成为获得新的AIT制剂的基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信